Effectiveness and Cost-Effectiveness Evaluations of AI-Assisted Diagnostic Software (VeriSee) for Ophthalmic Disease Screening
National Taiwan University Hospital
1,000 participants
Jun 2, 2025
INTERVENTIONAL
Conditions
Summary
This study aims to evaluate the effectiveness of an artificial intelligence (AI)-assisted screening system in ophthalmic diagnosis. Using AI-based fundus photography, the system will assist physicians in diagnosing three common eye diseases: age-related macular degeneration and diabetic retinopathy (DR). The AI system will analyze fundus images from participants and rapidly generate detection results for ophthalmologists' reference in making final diagnoses and clinical decisions. The study will assess the clinical benefits of the AI-assisted diagnostic system, providing scientific evidence to enhance the efficiency of ophthalmic disease diagnosis and treatment.
Eligibility
Inclusion Criteria2
- VeriSee AMD is used in non-retinal subspecialty ophthalmology clinics for adults aged 50 and above.
- VeriSee DR is used in non-retinal subspecialty clinics for diabetic patients aged 20 and above.
Exclusion Criteria1
- The patient does not agree to participate in the trial or is unable to provide informed consent.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
VeriSee AMD, VeriSee DR, and VeriSee GLC are AI-based medical software devices designed for screening age-related macular degeneration (AMD), diabetic retinopathy (DR), and glaucoma, respectively. These systems utilize advanced AI algorithms to analyze color fundus photography images for disease assessment. By installing the software on a computer, the system can evaluate image quality, predict disease conditions, and instantly provide results to clinical physicians, serving as a diagnostic aid.
Data collection from the patient's clinical history was conducted because the VeriSee AI-assisted diagnostic system was not used.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06843499